FDA approves expanded use for Abilify

NEW YORK The Food and Drug Administration has expanded the use of the Bristol-Myers Squibb and Otsuka Pharmaceuticals drug Abilify.

The drug is now approved to aid with the treatment of bipolar disorder. The companies said the FDA approved the drug as a secondary therapy alongside lithium and valproate for treating bipolar episodes in adults.

In 2007, Abilify had sales of over $1.78 billion, according to the FDA.